Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects

Author(s): Jagan M.R. Patlolla, Chinthalapally V. Rao

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 1 , 2012

Become EABM
Become Reviewer
Call for Editor


Triterpenoids are ubiquitous in the plant kingdom. Recent evidences support the beneficial effects of naturallyoccurring triterpenoids against several types of human diseases, including various cancers. Here, we have summarized the potential of triterpenoids belonging to the lupane, oleanane, ursane, and cucurbitacin groups, and their beneficial effects based on both laboratory and clinical investigations. Anticancer potential of triterpenoids and their anti-inflammatory, anti-proliferative, and pro-apoptotic effects have been discussed both in in vitro and in vivo models. Importantly, a large number of preclinical efficacy studies using chemically-induced, as well as tumor xenograft models provided evidence that both naturally occurring and synthetic derivatives had chemopreventive and therapeutic effects. In this review, we have highlighted several studies on chemopreventive and anticancer potential of triterpenoids based on various preclinical animal models of colon, breast, prostate, and melanoma cancers. Also, we made an attempt in discussing various mechanisms by which triterpenoids regulate various transcription and growth factors, inflammatory cytokines, and intracellular signaling pathways involved in cancer cell proliferation, apoptosis and tumor angiogenesis.

Keywords: Animal models, anti-inflammatory, bioavailability, cancer prevention, cancer treatment, pentacylic triterpenoids, triterpenoid derivatives, cancers, lupane, oleanane, ursane, cucurbitacin groups, anti-proliferative, pro-apoptotic effects

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [147 - 155]
Pages: 9
DOI: 10.2174/138920112798868719

Article Metrics

PDF: 170